All In Biotech

NDA 011525 · Renew Pharms

Ic-Green

Indocyanine Green · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

Feb 9, 1959

Approved uses

2

Original approval plus efficacy supplements

Registered trials

249

28 Phase 3, 43 recruiting

FAERS reports

121

105 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 30, 2026.

• Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients aged 1 month and older ( 1.1 ) • Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older ( 1.2 ) • Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer ( 1.3 ) • Ophthalmic angiography in adults and pediatric patients ( 1.4 ) 1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion IC-GREEN is indicated for fluorescence imaging of vessels (micro- and macro- vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients aged 1 month and older. 1.2 Visualization of Extrahepatic Biliary Ducts IC-GREEN is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older . 1.3 Lymphatic Mapping of Cervical and Uterine Cancer IC-GREEN is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management . 1.4 Ophthalmic Angiography IC-GREEN is indicated for use in ophthalmic angiography in adults and pediatric patients.

Mechanism: When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 5, 2024 Supplement 39 · Efficacy LetterLabel
  • Feb 9, 1959 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • IC-GREEN · INDOCYANINE GREEN 10MG/VIAL · INJECTABLE, INJECTION · Prescription
  • IC-GREEN · INDOCYANINE GREEN 25MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • IC-GREEN · INDOCYANINE GREEN 40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • IC-GREEN · INDOCYANINE GREEN 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Indocyanine Green" as an intervention, any sponsor and status, largest first.

All 249 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • palpitations10
  • urticaria10
  • off label use9
  • visual acuity reduced9
  • drug ineffective8
  • dyspnoea8
  • haemangioma congenital8
  • low birth weight baby8
  • patent ductus arteriosus8
  • rash8
  • disease progression7
  • hypotension7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20093
20102
20112
20126
20145
20152
20168
20178
201817
20197
20205
20213
202213
202311
20246
202511
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,192 on PubMed

Sponsor: Renew Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.